Condition
Systemic Treatment
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Terminated1
Completed1
Unknown1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06254248Phase 2Recruiting
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
NCT06277206Completed
A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma
NCT05927636Unknown
Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count
NCT03743961TerminatedPrimary
Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia
Showing all 4 trials